UY31695A - Cristal de compuestos de bencimidazol - Google Patents

Cristal de compuestos de bencimidazol

Info

Publication number
UY31695A
UY31695A UY0001031695A UY31695A UY31695A UY 31695 A UY31695 A UY 31695A UY 0001031695 A UY0001031695 A UY 0001031695A UY 31695 A UY31695 A UY 31695A UY 31695 A UY31695 A UY 31695A
Authority
UY
Uruguay
Prior art keywords
bencimidazol
composite crystal
methyl
crystal
trifluoroethoxy
Prior art date
Application number
UY0001031695A
Other languages
English (en)
Inventor
Hashimoto Hideo
Urai Tadashi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40577894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31695(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY31695A publication Critical patent/UY31695A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se provee un cristal de (R)-2-[[[3-metil-4-(2,2,2-trifluoroetoxi-2-piridinil]metil]sulfinil]-1H-bencimidazol que muestra un patrón de análisis de difracción de rayos X de polvo con picos característicos en espacios interplanos (d) de 10,06+0,2, 8,70+0,2, 6,57+0,2,5,59+0,2 y 4,00+0,2 Angstroms. La presente invención provee un fármaco antiúlcera estable superior en la absorbabilidad.
UY0001031695A 2008-03-10 2009-03-09 Cristal de compuestos de bencimidazol UY31695A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008059342 2008-03-10

Publications (1)

Publication Number Publication Date
UY31695A true UY31695A (es) 2009-11-10

Family

ID=40577894

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031695A UY31695A (es) 2008-03-10 2009-03-09 Cristal de compuestos de bencimidazol

Country Status (30)

Country Link
US (1) US8222422B2 (es)
EP (1) EP2262790B1 (es)
JP (3) JP2011513202A (es)
KR (1) KR20100123758A (es)
CN (1) CN102026994B (es)
AR (1) AR070972A1 (es)
AU (1) AU2009224247B2 (es)
BR (1) BRPI0909651A2 (es)
CA (1) CA2671369C (es)
CL (1) CL2009000547A1 (es)
CO (1) CO6300956A2 (es)
CR (1) CR11707A (es)
DO (1) DOP2010000274A (es)
EA (1) EA017064B1 (es)
EC (1) ECSP10010531A (es)
ES (1) ES2638463T3 (es)
GE (1) GEP20125649B (es)
IL (1) IL207867A0 (es)
LT (1) LT2262790T (es)
MA (1) MA32215B1 (es)
MX (1) MX2010009641A (es)
MY (1) MY150833A (es)
NZ (1) NZ588379A (es)
PE (1) PE20091680A1 (es)
PT (1) PT2262790T (es)
TW (1) TWI447110B (es)
UA (1) UA103189C2 (es)
UY (1) UY31695A (es)
WO (1) WO2009113696A1 (es)
ZA (1) ZA201006754B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
CN102108077B (zh) * 2009-12-23 2013-09-25 江苏豪森医药集团有限公司 制备右兰索拉唑的方法
US20130197232A1 (en) * 2010-01-29 2013-08-01 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
CN104447695A (zh) * 2013-11-22 2015-03-25 广东东阳光药业有限公司 一种苯并咪唑化合物的水合物
KR20160144927A (ko) 2015-06-08 2016-12-19 씨제이헬스케어 주식회사 야간 산 분비에 대한 벤즈이미다졸 유도체의 용도
IL301470A (en) * 2016-11-29 2023-05-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
CN106866631A (zh) * 2017-04-06 2017-06-20 山东裕欣药业有限公司 一种右旋兰索拉唑晶型及制备方法
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CN117843645A (zh) * 2018-05-25 2024-04-09 伊马拉公司 一种pde9抑制剂的一水合物和结晶形态
JPWO2020013330A1 (ja) * 2018-07-13 2021-06-24 協和発酵バイオ株式会社 ユーコミン酸の非溶媒和物結晶及びその製造方法
CN113376273B (zh) * 2021-06-02 2023-03-17 国药集团精方（安徽）药业股份有限公司 一种清心莲子饮hplc特征图谱的检测方法及该特征图谱的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
TR199901101T2 (xx) 1996-11-22 1999-07-21 The Procter & Gamble Company Gastroenstentinal hastal�klar�n tedavisine y�nelik bizmut ve nsaid i�eren bile�imler.
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
DK0987256T3 (da) * 1997-08-08 2002-02-11 Aventis Pharma Gmbh Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
JP2002501897A (ja) 1998-01-30 2002-01-22 セプラコール， インク． Ｒ−ランソプラゾール組成物及び方法
JP2002501896A (ja) 1998-01-30 2002-01-22 セプラコール， インク． Ｓ−ランソプラゾール組成物及び方法
AU3596199A (en) 1998-05-06 1999-11-23 Kobenhavns Universitet Treatment of celiac disease
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
CA2409044C (en) 2000-05-15 2013-02-19 Takeda Chemical Industries, Ltd. Improved recrystallization processes for obtaining anhydrous optically active lansoprazole
JP3374314B2 (ja) * 2000-05-15 2003-02-04 武田薬品工業株式会社 結晶の製造法
JP4327424B2 (ja) * 2000-05-15 2009-09-09 武田薬品工業株式会社 結晶の製造法
JP4160293B2 (ja) * 2000-12-01 2008-10-01 武田薬品工業株式会社 結晶の製造法
CA2436825C (en) * 2000-12-01 2011-01-18 Takeda Chemical Industries, Ltd. Process for the crystallization of (r)- or (s)-lansoprazole
WO2004035052A1 (ja) 2002-10-16 2004-04-29 Takeda Pharmaceutical Company Limited 安定な固形製剤
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
WO2009088857A1 (en) 2007-12-31 2009-07-16 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r) -2- [ [ [3-methyl-4- (2, 2, 2-trifluoroethoxy) -2-pyridinyl] methyl] sulfinyl] -1h-benz imidazole

Also Published As

Publication number Publication date
LT2262790T (lt) 2017-08-25
MY150833A (en) 2014-02-28
CN102026994B (zh) 2014-05-07
AU2009224247A2 (en) 2010-10-28
MA32215B1 (fr) 2011-04-01
JP2011513202A (ja) 2011-04-28
NZ588379A (en) 2012-07-27
WO2009113696A1 (en) 2009-09-17
ZA201006754B (en) 2011-11-30
AR070972A1 (es) 2010-05-19
GEP20125649B (en) 2012-09-25
EA017064B1 (ru) 2012-09-28
EP2262790B1 (en) 2017-06-07
UA103189C2 (ru) 2013-09-25
JP2015163623A (ja) 2015-09-10
AU2009224247B2 (en) 2013-12-12
CR11707A (es) 2010-11-04
PE20091680A1 (es) 2009-11-16
EA201071053A1 (ru) 2011-04-29
PT2262790T (pt) 2017-07-18
TWI447110B (zh) 2014-08-01
IL207867A0 (en) 2010-12-30
ES2638463T3 (es) 2017-10-20
CO6300956A2 (es) 2011-07-21
DOP2010000274A (es) 2010-09-30
AU2009224247A1 (en) 2009-09-17
CL2009000547A1 (es) 2010-05-07
CA2671369C (en) 2011-05-10
US8222422B2 (en) 2012-07-17
KR20100123758A (ko) 2010-11-24
US20110046183A1 (en) 2011-02-24
CN102026994A (zh) 2011-04-20
MX2010009641A (es) 2010-09-22
BRPI0909651A2 (pt) 2015-09-22
TW200938531A (en) 2009-09-16
CA2671369A1 (en) 2009-09-10
JP2014015477A (ja) 2014-01-30
EP2262790A1 (en) 2010-12-22
ECSP10010531A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
UY31695A (es) Cristal de compuestos de bencimidazol
ATE498618T1 (de) Neue zyklische harnstoffderivate, deren herstellung und pharmazeutische verwendung damit als kinase-inhibitoren
BRPI0820419A2 (pt) "arranjos, conjuntos e métodos de filtro de ar"
TWI340141B (en) Composition for forming prism layer and prism film manufactured using the same
EP1883438A4 (en) Apparatus and techniques for reducing the effects of general anesthetics
DE502005010912D1 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
FI20055416A0 (fi) Bioabsorvoituva nauhajärjestelmä, bioabsorboituva nauha, menetelmä bioabsorboituvan nauhan valmistamiseksi, bioabsorboituvan nauhan neulajärjestelmä sekä lukitusmekanismi
ATE372998T1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
EP2143713A4 (en) NEW PYRROLINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING THIS
ATE433958T1 (de) Glucocorticoid-mimetika, verfahren zu deren herstellung, pharmazeutische zusammensetzungen und deren verwendung
ATE453637T1 (de) N-(aminoheteroaryl)-1h-indol-2-carboxamid- derivate sowie deren herstellung und therapeutische anwendung
HK1125110A1 (en) Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
ATE538125T1 (de) Neue 2-azaindol-derivate, deren herstellung und pharmazeutische verwendung als kinase-inhibitoren
DE602006001272D1 (de) Narkosebox und Mikroskop
ATE542806T1 (de) Diarylmethylpiperazinderivate, deren herstellung und deren verwendung
EP1834624A4 (en) MEDICAL COMPOSITION AND MANUFACTURING METHOD THEREFOR
EP2127733A4 (en) HYDROGEN-SOLUBLE FILM AND METHOD OF MANUFACTURING THEREOF
ATE462408T1 (de) Pharmazeutische zusammensetzungen, enthaltend valatograst, und verfahren zu deren herstellung
ATE420118T1 (de) Biotinylierte hexadecasaccharide, pharmazeutische zusammensetzungen daraus und deren verwendung
ATE388936T1 (de) 9-chloro-15-deoxyprostaglandinderivate, verfahren zu ihrer herstellung und deren verwendung als medikamente
DE112007001661A5 (de) Neue wasserstoffreiche 1,3-Dialkoxy-disiloxane sowie Verfahren zu deren Herstellung und deren Verwendung
ATE435877T1 (de) Polymernitroxide sowie ihre herstellung und verwendung
DE602006008971D1 (de) N-ä(4,5-diphenylpyrimidin-2-yl)methylüaminderivate, deren herstellung und deren therapeutische verwendung
ZA200803335B (en) Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
ATE482962T1 (de) Verfahren zur herstellung funktionalisierter fünfringheterocyclen und deren verwendung

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181017